These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 19538102

  • 1. Diabetes medications and body weight.
    Mitri J, Hamdy O.
    Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
    [Abstract] [Full Text] [Related]

  • 2. What to add in with metformin in type 2 diabetes?
    Petrie JR, Adler A, Vella S.
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [Abstract] [Full Text] [Related]

  • 3. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 4. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 5. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
    Hermansen K, Mortensen LS.
    Drug Saf; 2007 Jul; 30(12):1127-42. PubMed ID: 18035865
    [Abstract] [Full Text] [Related]

  • 6. Weight changes following the initiation of new anti-hyperglycaemic therapies.
    Nichols GA, Gomez-Caminero A.
    Diabetes Obes Metab; 2007 Jan; 9(1):96-102. PubMed ID: 17199724
    [Abstract] [Full Text] [Related]

  • 7. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 8. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ.
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [Abstract] [Full Text] [Related]

  • 9. [Development of body weight during antidiabetic treatment].
    Hamann A.
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S255-8. PubMed ID: 17139582
    [Abstract] [Full Text] [Related]

  • 10. Insulin treatment and the problem of weight gain in type 2 diabetes.
    Carver C.
    Diabetes Educ; 2006 Dec; 32(6):910-7. PubMed ID: 17102158
    [Abstract] [Full Text] [Related]

  • 11. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR, Dhakal-Karki S, Dunican KC.
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [Abstract] [Full Text] [Related]

  • 12. Metformin and body weight.
    Golay A.
    Int J Obes (Lond); 2008 Jan; 32(1):61-72. PubMed ID: 17653063
    [Abstract] [Full Text] [Related]

  • 13. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 14. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association.
    Circulation; 2003 Dec 09; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract] [Full Text] [Related]

  • 15. Which oral agent to use when metformin is no longer effective?
    Bannon M.
    QJM; 2011 Mar 09; 104(3):183-4. PubMed ID: 21330402
    [No Abstract] [Full Text] [Related]

  • 16. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
    Wilding J.
    Int J Clin Pract; 2006 Oct 09; 60(10):1272-80. PubMed ID: 16981971
    [Abstract] [Full Text] [Related]

  • 17. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
    Peters AL.
    Cleve Clin J Med; 2009 Dec 09; 76 Suppl 5():S20-7. PubMed ID: 19952300
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacologic treatment of diabetes].
    De Montigny P, Clerc C, Descarpentries C.
    Perspect Infirm; 2006 Dec 09; 4(2):30-4. PubMed ID: 17184094
    [No Abstract] [Full Text] [Related]

  • 19. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M, Astrup A.
    Obes Rev; 2007 Sep 09; 8(5):381-4. PubMed ID: 17716295
    [Abstract] [Full Text] [Related]

  • 20. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
    Purnell JQ, Weyer C.
    Treat Endocrinol; 2003 Sep 09; 2(1):33-47. PubMed ID: 15871553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.